Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

New England Journal of Medicine

Volumn 359, Issue 12, 2008, Pages 1238-1251

  Sacco, Ralph L ^a   Diener, Hans Christoph ^b   Yusuf, Salim ^d   Cotton, Daniel ^h   Ôunpuu, Stephanie ^f   Lawton, William A ⁱ   Palesch, Yuko ^k   Martin, Reneé H ^k   Albers, Gregory W ^l   Bath, Philip ^j   Bornstein, Natan ^m   Chan, Bernard P L ⁿ   Chen, Sien Tsong ^o   Cunha, Luis ^p   Dahlöf, Björn ^q   De Keyser, Jacques ^r   Donnan, Geoffrey A ^s   Estol, Conrado ^t   Gorelick, Philip ^u   Gu, Vivian ^v   Hermansson, Karin ^x   Hilbrich, Lutz ^h   Kaste, Markku ^y   Lu, Chuanzhen ^w   Machnig, Thomas ^c   Pais, Prem ^z   Roberts, Robin ^e   Skvortsova, Veronika ^aa   Teal, Philip ^g   Toni, Danilo ^ab   Vander Maelen, Cam ^h   Voigt, Thor ^h   Weber, Michael ^ac   Yoon, Byung Woo ^ad   more..

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d HAMILTON HEALTH SCIENCES   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

ⁱ BOEHRINGER INGELHEIM LTD   (United Kingdom)

^j UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^k Med Univ S Carolina 135 C   (United States)

^l STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^m Ichilov Medical Centre   (Israel)

ⁿ NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^o CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^p CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^q SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^r UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^s UNIVERSITY OF MELBOURNE   (Australia)

^t Neurological Center for Treatment and Research   (Argentina)

^u UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^v Boehringer Ingelheim Shanghai Pharmaceuticals Co Ltd   (China)

^w FUDAN UNIVERSITY   (China)

^x Boehringer Ingelheim AB   (Sweden)

^y UNIVERSITY OF HELSINKI   (Finland)

^z ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^aa PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^ab SAPIENZA UNIVERSITY OF ROME   (Italy)

^ac SUNY Downstate Medical Center   (United States)

^ad Seoul National University Hospital   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPYRIDAMOLE; ANTITHROMBOCYTIC AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG DERIVATIVE; TELMISARTAN; TICLOPIDINE;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RECURRENT DISEASE; STROKE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; VOMITING; BLEEDING; BRAIN ISCHEMIA; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DRUG COMBINATION; FACTORIAL ANALYSIS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK; VASCULAR DISEASE;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; BENZIMIDAZOLES; BENZOATES; BRAIN ISCHEMIA; DELAYED-ACTION PREPARATIONS; DIPYRIDAMOLE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FACTOR ANALYSIS, STATISTICAL; FEMALE; HEMORRHAGE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK; STROKE; TICLOPIDINE; VASCULAR DISEASES;

EID: 51449116270     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0805002     Document Type: Article

References (32)

1. Dhamoon MS, Sciacca RR, Rundek T, Sacco RL, Elkind MS. Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study. Neurology 2006;66:641-6.
2. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1:1215-20.
3. Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501-7.
4. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329-39.
5. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143:1-13.
6. Mohr JP, Thompson JLP, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444-51.
7. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
8. [Erratum, BMJ 2002;324:141.]
9. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-7.
10. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005;352: 1305-16.
11. The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006;367:1665-73.
12. [Erratum, Lancet 2007;369:274.]
13. Idem. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol 2007;6:115-24.
14. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006;37:577-617.
15. European Stroke Organization (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008;25:457-507.
16. Thijs V, Lemmens R, Fieuws S. Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke. Eur Heart J 2008;29:1086-92.
17. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
18. Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17.
19. Hirsh J, Guyatt G, Albers GW, Schünemann HJ. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: evidence-based guidelines. Chest 2004;126:Suppl:172S-173S.
20. Diener HC, Sacco R, Yusuf S. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis 2007;23:368-80.
21. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST: Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
22. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19: 604-7.
23. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J 1965;14:61-5.
24. Haybittle JL. Repeated assessment of results in clinical trials of cancer treatment. Br JRadiol 1971;44:793-7.
25. Fisher LD, Gent M, Büller HR Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. Am Heart J 2001;141:26-32.
26. Gorelick PB, Richardson D, Kelly M, et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 2003;289:2947-57.
27. Laster LL, Johnson MF. Non-inferiority trials: the 'at least as good as' criterion. Stat Med 2003;22:187-200.
28. Wang S-J, Hung HMJ. TACT method for non-inferiority testing in active controlled trials. Stat Med 2003;22:227-38.
29. Fleming TR. Current issues in non-inferiority trials. Stat Med 2008;27:317-32.
30. James Hung HM, Wang S-J, Tsong Y, Lawrence J, O'Neil RT. Some fundamental issues with non-inferiority testing in active controlled trials. Stat Med 2003;22: 213-25.
31. D'Agostino RB, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics. Stat Med 2003;22:169-86.
32. Akhtar M, Ordovas K, Martin A, Higgins CB, Michaels AD. Effect of chronic sustained-release dipyridamole on myocardial blood flow and left ventricular function in patients with ischemic cardiomyopathy. Congest Heart Fail 2007;13: 130-5.